Curative Proton Therapy for Infants: At What Cost?

IF 6.5 1区 医学 Q1 ONCOLOGY International Journal of Radiation Oncology Biology Physics Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI:10.1016/j.ijrobp.2024.11.017
D. Indelicato , J. Bradley , D. Klawinski , P. Aldana , E. Sandler , C. Morris , R. Mailhot
{"title":"Curative Proton Therapy for Infants: At What Cost?","authors":"D. Indelicato ,&nbsp;J. Bradley ,&nbsp;D. Klawinski ,&nbsp;P. Aldana ,&nbsp;E. Sandler ,&nbsp;C. Morris ,&nbsp;R. Mailhot","doi":"10.1016/j.ijrobp.2024.11.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Infants (age 12 months and younger) are the most difficult population of cancer patients to treat. Historically, radiation would be excluded from treatment options and this view remains prevalent worldwide. New radiation technology may shift this perspective. The purpose of this study is to report the outcomes of infants undergoing treatment with curative-intent proton therapy.</div></div><div><h3>Methods</h3><div>Between 2006-2023, 15 infants with a median age of 11 months (range, 7-12 months) were irradiated at the University of Florida, constituting 0.75% of all pediatric patients treated with curative intent during this period. Eight patients were male and none had metastatic disease. The diagnoses included rhabdomyosarcoma (7), Ewing sarcoma (2), ATRT (1), ependymoma (1), and pineoblastoma (1). All patients were treated with standard radiation doses for their disease and the mean was 50.4 GyRBE (range, 41.1-54). 14/15 patients received disease-specific multi-agent chemotherapy. Cumulative incidence method was used to estimate overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and local control (LC).</div></div><div><h3>Results</h3><div>With a median followup of 3.5 years (range, 01.-11.2 years), the 5 year OS, CSS, PFS, and LC was 58%, 65%, 58%, and 72%, respectively. Two and 5 patients had leptomeningeal and local recurrence, respectively. One patient died from a 1 metachronous rhabdoid tumor in lungs and kidneys. No patients were lost to follow-up. Four of 7 surviving patients experienced serious toxicity including blindness, deafness, vasculopathy and cataracts requiring surgery, global developmental delay, panhypopituitarism, hemorrhagic cystitis, and severe dentofacial and musculoskeletal problems.</div></div><div><h3>Conclusion</h3><div>When proton therapy is utilized as part of a multimodality treatment plan in infants with sarcoma and brain tumors, survival is possible but often comes at the cost of major toxicity. Improvements in patient selection may take us farther than improvements in technology.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Page e3"},"PeriodicalIF":6.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624035910","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Infants (age 12 months and younger) are the most difficult population of cancer patients to treat. Historically, radiation would be excluded from treatment options and this view remains prevalent worldwide. New radiation technology may shift this perspective. The purpose of this study is to report the outcomes of infants undergoing treatment with curative-intent proton therapy.

Methods

Between 2006-2023, 15 infants with a median age of 11 months (range, 7-12 months) were irradiated at the University of Florida, constituting 0.75% of all pediatric patients treated with curative intent during this period. Eight patients were male and none had metastatic disease. The diagnoses included rhabdomyosarcoma (7), Ewing sarcoma (2), ATRT (1), ependymoma (1), and pineoblastoma (1). All patients were treated with standard radiation doses for their disease and the mean was 50.4 GyRBE (range, 41.1-54). 14/15 patients received disease-specific multi-agent chemotherapy. Cumulative incidence method was used to estimate overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and local control (LC).

Results

With a median followup of 3.5 years (range, 01.-11.2 years), the 5 year OS, CSS, PFS, and LC was 58%, 65%, 58%, and 72%, respectively. Two and 5 patients had leptomeningeal and local recurrence, respectively. One patient died from a 1 metachronous rhabdoid tumor in lungs and kidneys. No patients were lost to follow-up. Four of 7 surviving patients experienced serious toxicity including blindness, deafness, vasculopathy and cataracts requiring surgery, global developmental delay, panhypopituitarism, hemorrhagic cystitis, and severe dentofacial and musculoskeletal problems.

Conclusion

When proton therapy is utilized as part of a multimodality treatment plan in infants with sarcoma and brain tumors, survival is possible but often comes at the cost of major toxicity. Improvements in patient selection may take us farther than improvements in technology.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
婴儿质子治疗:成本是多少?
目的:婴儿(12个月及以下)是癌症患者中最难治疗的人群。从历史上看,放疗被排除在治疗方案之外,这一观点在世界范围内仍然普遍存在。新的辐射技术可能会改变这种观点。本研究的目的是报道婴儿接受治疗意图质子治疗的结果。方法:2006-2023年间,15名中位年龄为11个月(范围7-12个月)的婴儿在佛罗里达大学接受了放射治疗,占该期间以治愈为目的接受治疗的所有儿科患者的0.75%。8例患者为男性,无转移性疾病。诊断包括横纹肌肉瘤(7例)、尤文氏肉瘤(2例)、ATRT(1例)、室管膜瘤(1例)和松果母细胞瘤(1例)。所有患者均接受标准放射剂量治疗,平均剂量为50.4 GyRBE(范围41.1-54)。14/15的患者接受了疾病特异性多药化疗。累积发生率法用于估计总生存期(OS)、病因特异性生存期(CSS)、无进展生存期(PFS)和局部控制期(LC)。结果中位随访3.5年(01 ~ 11.2年),5年OS、CSS、PFS、LC分别为58%、65%、58%、72%。脑膜轻症复发2例,局部复发5例。1例患者死于肺和肾脏异时性横纹肌样肿瘤。无患者失访。7名幸存患者中有4名出现严重毒性,包括失明、耳聋、血管病变和需要手术的白内障、整体发育迟缓、垂体功能减退、出血性膀胱炎以及严重的牙面和肌肉骨骼问题。结论:当质子治疗作为多模式治疗计划的一部分用于婴儿肉瘤和脑肿瘤时,生存是可能的,但往往是以主要毒性为代价的。在病人选择上的改进可能比技术上的改进能让我们走得更远。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
Erratum to 'Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer.' International Journal of Radiation Oncology*Biology*Physics, Volume 120, Issue 2, 1 October 2024, Pages 332-342. Stereotactic Reirradiation: Final Results From a Phase 1 Dose Escalation Trial (DESTROY-1) Perilesional Edema as a Predictor of Local Failure in Metastatic Brain Lesions Treated With Stereotactic Radiosurgery: A Systematic Review and Meta-Analysis Long-term Results From a Phase 1 Study of Spinal Cord Constraint Relaxation With Single Session Spine Stereotactic Radiosurgery in the Primary Management of Patients With Inoperable, Previously Unirradiated Spinal Metastases With Epidural Extension Radiosurgical Management of Cavernous Sinus Hemangioma: Systematic Review, Meta-analysis, and International Stereotactic Radiosurgery Society Practice Guideline
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1